scholarly journals A Pitfall in the Management of Acute Right Ventricular Failure Treated with Inhaled Nitric Oxide: A Case of Rebound Pulmonary Hypertension

2016 ◽  
Vol 22 (8) ◽  
pp. S132 ◽  
Author(s):  
Kelsey Flint ◽  
Steven Bradley
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Right Ventricular ◽  
Right Ventricular Failure ◽  
Inhaled Nitric Oxide ◽  
Ventricular Failure ◽  
Acute Right Ventricular Failure

Use of Inhaled Nitric Oxide in Treatment of Right Ventricular Failure after Heart Transplantation

1994 ◽  
Vol 81 (SUPPLEMENT) ◽  
pp. A126 ◽  
Author(s):  
C. Dubois ◽  
de Lentdecker ◽  
R. Guillemain ◽  
D. Brodaty ◽  
S. Schlumberger ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Transplantation ◽  
Right Ventricular ◽  
Right Ventricular Failure ◽  
Inhaled Nitric Oxide ◽  
Ventricular Failure

Inhaled Nitric Oxide Improves Hepatic Tissue Oxygenation in Right Ventricular Failure

1995 ◽  
Vol 82 (2) ◽  
pp. 588-590 ◽  
Author(s):  
Claire Gatecel ◽  
Alexandre Mebazaa ◽  
Robert Kong ◽  
Nathalie Guinard ◽  
Nathalie Kermarrec ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Right Ventricular ◽  
Tissue Oxygenation ◽  
Right Ventricular Failure ◽  
Inhaled Nitric Oxide ◽  
Hepatic Tissue ◽  
Ventricular Failure

scholarly journals Inhaled Pulmonary Vasodilators and Thoracic Organ Transplantation: Does Evidence Support Its Use and Cost Benefit?

2019 ◽  
Vol 24 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Ryan Krebs ◽  
Yoshihisa Morita
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Heart Transplantation ◽  
Lung Transplantation ◽  
Right Ventricular ◽  
Right Ventricular Failure ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Ventricular Failure ◽  
Pulmonary Vasodilators

In heart transplantation, pulmonary hypertension and increased pulmonary vascular resistance followed by donor right ventricular dysfunction remain a major cause of perioperative morbidity and mortality. In lung transplantation, primary graft dysfunction remains a major obstacle because it can cause bronchiolitis obliterans and mortality. Pulmonary vasodilators have been used as an adjunct therapy for heart or lung transplantation, mainly to treat pulmonary hypertension, right ventricular failure, and associated refractory hypoxemia. Among pulmonary vasodilators, inhaled nitric oxide is unique in that it is selective in pulmonary circulation and causes fewer systemic complications such as hypotension, flushing, or coagulopathy. Nitric oxide is expected to prevent or attenuate primary graft dysfunction by decreasing ischemia-reperfusion injury in lung transplantation. However, when considering the long-term benefit of these medications, little evidence supports their use in heart or lung transplantation. Current guidelines endorse inhaled vasodilators for managing immediate postoperative right ventricular failure in lung or heart transplantation, but no guidance is offered regarding agent selection, dosing, or administration. This review presents the current evidence of inhaled nitric oxide in lung or heart transplantation as well as comparisons with other pulmonary vasodilators including cost differences in consideration of economic pressures to contain rising pharmacy costs.

Sign in / Sign up

Export Citation Format

Share Document